OncoMatch/Clinical Trials/NCT06529822
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Is NCT06529822 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Synthetic long peptide personalized cancer vaccine and Poly ICLC for muscle-invasive bladder carcinoma.
Treatment: Synthetic long peptide personalized cancer vaccine · Poly ICLC · Signatera assay — This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Urothelial Carcinoma
Gastric Cancer
Esophageal Carcinoma
Disease stage
Required: Stage PT2-4AN0M0, PT0-4AN+M0, T1 N1-3 M0, T2-4 N0-2M0, T1-2 N1-3 M0, T3-4 N0-3 M0, II, III (AJCC 8th edition)
TNM classification (based on the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th ed.) at pathological examination of surgical resection specimen as follows: pT2-4aN0M0 or pT0-4aN+M0 [MIBC/UTUC]; Esophageal and Esophagogastric junction adenocarcinoma T1 N1-3 M0 or T2-4 N0-2M0; Gastric adenocarcinoma T1-2 N1-3 M0 or T3-4 N0-3 M0; Stage II or III gastroesophageal adenocarcinoma (GEC).
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
WBC ≥ 1.5 K/cumm; Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 50 K/cumm; Hemoglobin ≥ 8.0 g/dL
Kidney function
Creatinine clearance > 30 mL/min by Cockcroft-Gault
Liver function
Total bilirubin ≤ 1.5 x IULN; AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
Adequate bone marrow and organ function as defined below: WBC ≥ 1.5 K/cumm; Absolute neutrophil count ≥ 1.0 K/cumm; Platelets ≥ 50 K/cumm; Hemoglobin ≥ 8.0 g/dL; Total bilirubin ≤ 1.5 x IULN; AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN; Creatinine clearance > 30 mL/min by Cockcroft-Gault
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify